Ondine Presented Steriwave Data at IPC 2026
Summary by AI BETAClose X
30 April 2026
ONDINE BIOMEDICAL INC.
("Ondine" or the "Company")
Ondine Biomedical Presented Steriwave Data at Recent Infection Prevention and Control Conference (IPC 2026)
Ondine Biomedical Inc. (LON: OBI), a leader in light-activated antimicrobial therapies, announces that its President and Chief Technology Officer, Dr. Nicolas Loebel, was a featured speaker at the Infection Prevention and Control ("IPC") Conference. The event took place 28-29 April at The National Conference Centre in Birmingham and brought together leading clinicians, infection prevention specialists, and NHS decision-makers from across the UK.
The IPC Conference 2026 featured sessions addressing strategies to reduce healthcare-associated infections ("HAIs"), improve antimicrobial stewardship, and address operational pressures within the NHS. The program included expert-led sessions on surveillance and early identification of infection risks, practical containment strategies, and scalable interventions to improve patient safety while reducing costs. The conference also highlighted the urgent need for innovation-driven solutions to address increasing surgical backlogs, workforce constraints, and the growing burden of antimicrobial resistance ("AMR").
In alignment with the conference's focus on evidence-based best practices and innovation adoption, Ondine Biomedical presented clinical outcomes associated with its Steriwave® nasal photodisinfection, which NHS Supply Chain recently classified as an Innovation Product. This classification reflects Steriwave's alignment with long-term NHS priorities, including reducing AMR, supporting infection prevention, and improving the efficiency and sustainability of healthcare delivery.
Dr. Loebel's presentation, titled "Nasal Photodisinfection: Addressing the Hidden Costs of HAIs", focused on the clinical and economic burden of healthcare-associated infections and the role of nasal decolonisation in reducing infection risk. The presentation highlighted limitations of traditional approaches and outlined how Steriwave nasal photodisinfection offers a compelling non-antibiotic alternative aligned with evolving antimicrobial stewardship priorities.
Key highlights from the presentation included:
· Burden of HAIs: Healthcare-associated infections drive significant clinical and economic impact, including increased length of stay, higher treatment costs, and reduced surgical capacity. With an average of 9.7 additional hospital days per major SSI, each infection can displace two to three subsequent surgical procedures.
· Limitations of antibiotic decolonisation: The presentation outlined challenges associated with antibiotic-based nasal decolonisation, including resistance development, multi-day treatment protocols, and disruption of the nasal microbiome.
· Photodisinfection mechanism and profile: Steriwave nasal photodisinfection was presented as a rapid, single-dose, broad-spectrum antimicrobial approach designed to eliminate nasal pathogens without contributing to antimicrobial resistance. The nurse-led application supports consistent, high compliance.
· Clinical and real-world data: Data from Steriwave use across multiple clinical and real-world settings in Canada and the UK were presented, including reductions in surgical site infections and ICU-acquired pneumonia. These findings were associated with shorter lengths of stay, faster recovery, and improved patient flow, supporting hospitals in reclaiming bed capacity and increasing procedural throughput.
· Health economic impact: Health economic analysis of Steriwave was highlighted, demonstrating substantial reductions in infection-related costs and improved hospital efficiency, supporting more sustainable NHS operations.
Dr. Nicolas Loebel remarked:
"Hospital-acquired infections are not only a clinical challenge but also place a significant logistical and financial burden on healthcare systems. Our nasal photodisinfection helps clinicians to proactively protect patients while improving efficiency and capacity within their facilities in an era of rising antimicrobial resistance."
Carolyn Cross, Ondine's CEO added:
"Ondine's participation in IPC 2026 reflects the growing interest we are seeing in the UK market and engagement with NHS institutions around non-antibiotic approaches to infection prevention. Steriwave's recent classification as an Innovation Product by NHS Supply Chain further reinforces this momentum and its alignment with NHS priorities, including improving patient outcomes while managing costs."
Enquiries:
|
Ondine Biomedical Inc. |
|
|
Carolyn Cross, CEO |
+1 604 669 0555 |
|
|
|
|
Strand Hanson Limited (Nominated Adviser & Joint Financial Adviser) |
|
|
James Harris, Richard Johnson |
+44 (0)20 7409 3494 |
|
|
|
|
Peel Hunt LLP (Joint Bookrunner and Broker, Joint Financial Adviser) |
|
|
James Steel, Sohail Akbar |
+44 (0)20 7418 8900 |
|
|
|
|
5654 & Company (Financial PR and IR Adviser) |
|
|
Matthew Neal, Chris Gardner, Melissa Gardiner |
+44 0791 7800 011 |
About Steriwave® and its Mode of Action
Steriwave nasal photodisinfection is a non-invasive and painless treatment that uses a proprietary light-activated photosensitive agent to destroy harmful bacteria, viruses, and fungi, including antibiotic-resistant strains, in the nasal passages. The procedure takes five minutes and, unlike antibiotics, is effective immediately and allows the normal nasal microbiome to recover quickly, without fostering antimicrobial resistance.
The two-step process involves applying the Steriwave formulation in the nostrils where it electrostatically binds to microbes rather than human cells. The area is then illuminated with safe red light to activate the formulation, triggering an oxidative burst that physically destroys all manner of pathogens within minutes. This rapid and overwhelming oxidative stress makes it extremely difficult for pathogens to develop resistance, and the process stops immediately once the light is turned off. Steriwave has been used in a growing number of hospitals since 2011.
About Ondine Biomedical Inc.
Ondine Biomedical Inc. is a Canadian life sciences company and leader in light-activated antimicrobial therapies ('photodisinfection') for the prevention and treatment of infections, including those caused by multidrug-resistant organisms. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection technology, in various stages of development.
Ondine's nasal photodisinfection system is CE-marked in Europe and is approved for nasal decolonisation in Canada, Australia, Mexico and several other countries under the name Steriwave®. In the US, it has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA and is currently undergoing clinical trials for regulatory approval. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns and other indications.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund